DDInter1215 DDInter927
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Mifepristone {u} (Compound) binds {v} (Gene) CYP3A5
Mifepristone {u} (Compound) upregulates {v} (Gene) CDK6
Mifepristone {u} (Compound) is included by {v} (Pharmacologic Class) Progestational Hormone Receptor Antagonists
Mifepristone {u} (Compound) downregulates {v} (Gene) ATP6V1D
Mifepristone {u} (Compound) causes {v} (Side Effect) Toxic shock syndrome
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naldemedine
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Mifepristone {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Mifepristone (Compound) binds CYP3A5 (Gene)
Mifepristone (Compound) upregulates CDK6 (Gene)
Mifepristone (Compound) is included by Progestational Hormone Receptor Antagonists (Pharmacologic Class)
Mifepristone (Compound) downregulates ATP6V1D (Gene)
Mifepristone (Compound) causes Toxic shock syndrome (Side Effect)
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Mifepristone may lead to a major life threatening interaction when taken with Daunorubicin